伴血脂异常IgA肾病临床病理特征的回顾性分析

Abstract
Figure/Table
References (24)
Related Citation (9)

Download: PDF (448 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the differences in clinicopathological features of IgA nephropathy with different dyslipidemia. Methods The clinicopathological data of 173 patients diagnosed as IgA nephropathy at the Second Hospital of Shanxi Medical University from August 2015 to August 2018 was collected. Patients with dyslipidemia were divided into hypercholesterolemia group, hypertriglyceridemia group, low high-density lipoproteinemia group and mixed hyperlipidemia group, while patients with normal blood lipids were used as a control group. The differences in clinicopathological parameters among five groups were compared, and a multiple stepwise regression model was established to investigate the estimated glomerular filtration rate (eGFR). Results The 24-hour urine protein level in the hypercholesterolemia group was higher than that in the control group, while serum albumin (Alb) was lower than that in the control group, and the differences were statistically significant (P ＜ 0.05). The proportion of males, age, body mass index (BMI), serum creatinine (Scr), uric acid (UA), and Oxford classification (T rating) in the hypertriglyceridemia group were higher than those in the control group, while eGFR was lower than that in the control group, and the differences were statistically significant (P ＜ 0.05). The proportion of males, BMI, Scr, UA and hemoglobin (Hb) in the low high-density lipoproteinemia group were higher than those in the control group, while the eGFR was lower than that in the control group, and the differences were statistically significant (P ＜ 0.05). BMI, 24 h urine protein quantitation and Hb in the mixed hyperlipidemia group were higher than those in the control group, while eGFR and Alb were lower than those in the control group, and the differences were statistically significant (P ＜ 0.05). The regression equation showed that gender, Hb and eGFR were positively correlated; age, UA, and Oxford classification were negatively correlated with eGFR. Conclusion The degree of clinical pathological damage in patients with IgA nephropathy with different dyslipidemia types is not completely the same, and hypertriglyceridemia might be a risk factor for renal interstitial fibrosis in IgA nephropathy.

Key words： IgA nephropathy Dyslipidemia Clinical indicators Renal pathology

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HOU Haizhu1 LUO Jing2 GUO Hui1

Cite this article:

HOU Haizhu1 LUO Jing2 GUO Hui1. Retrospective analysis of clinicopathological features of IgA nephropathy with dyslipidemia[J]. 中国医药导报, 2019, 16(27): 73-76,80.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I27/73

[1] Li M，Yu X. Genetic study of immunoglobulin A nephropathy：From research to clinical application [J]. Nephrology（Carlton），2018，23（S4）：26-31.
[2] Zhang YM，Zhang H. Update on treatment of immunoglobulin A nephropathy [J]. Nephrology（Carlton），2018，23（S4）：62-67.
[3] 张良，李志辉，银燕，等.儿童初发IgA肾病肾病综合征型的临床特点[J].中国当代儿科杂志，2015，17（8）：786-791.
[4] Syrj?覿nen J，Mustonen J，Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy [J]. Nephrol Dial Transplant，2000，15（1）：34-42.
[5] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南（2016年修订版）[J].中国循环杂志，2016，31（10）：937-950.
[6] Roberts IS，Cook HT，Troyanov S，et al. The Oxford classification of IgA nephropathy：pathology definitions，correlations，and reproducibility [J]. Kidney Int，2009，76（5）：546-556.
[7] 顾乡，马清，陈海平，等.慢性肾脏病心血管并发症及相关危险因素研究进展[J].中国中西医结合肾病杂志，2016， 17（2）：181-183.
[8] Cases A，Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients [J]. Kidney Int Suppl，2005，68（99）：S87-S93.
[9] Gyebi L，Soltani Z，Reisin E. Lipid nephrotoxicity：new concept for an old disease [J]. Curr Hypertens Rep，2012，14（2）：177-181.
[10] 赖玉萍，张舟，梁燕娟，等.IgA肾病血脂异常与临床病理分析[J].重庆医学，2016，45（32）：4511-4513，4516.
[11] 沈姗，柴华旗.高脂血症与IgA肾病临床病理的相关性分析[J].中国血液流变学杂志，2013，23（2）：268-270， 273.
[12] Hunsicker LG，Adler S，Caggiula A，et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study [J]. Kidney Int，1997，51（6）：1908-1919.
[13] Fried LF，Orchard TJ，Kasiske BL. Effect of lipid reduction on the progression of renal disease：a meta-analysis [J]. Kidney Int，2001，59（1）：260-269.
[14] 丁奕，田娜，周晓玲，等.肥胖与IgA肾病患者独立肾脏风险因子的相关性分析[J].中华肾脏病杂志，2017，33（5）：321-326.
[15] 宗艾伦，周迎生.体重波动对小鼠血糖水平的影响[J].中国实验动物学报，2018，26（6）：721-733.
[16] 贾冬霞，彭君臣，刘思泰，等.老年肥胖患者血浆视黄醇结合蛋白4水平与血压及胰岛素抵抗相关性研究[J].中国现代医生，2017，55（21）：1-3.
[17] Sasatomi Y，Tada M，Uesugi N，et al. Obesity associated with hypertension or hyperlipidemia accelerates renal damage [J]. Pathobiology，2001，69（2）：113-118.
[18] Buemi M，Allegra A，Corica F，et al. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nep-hropathy [J]. Clin Pharmacol Ther，2000，67（4）：427-431.
[19] 乐宇娜.阿托伐他汀联合贝那普利对IgA肾病患者蛋白尿的影响[J].中国基层医药，2018，25（10）：1307-1310.
[20] 赵晓兰，崔秀珍.黄芪建中汤加减对慢性肾炎患者免疫应答的影响[J].世界中医药，2018，13（9）：2229-2232.
[21] 赵大坤，王婧，刘丽，等.格列喹酮联合阿托伐他汀治疗早期糖尿病肾病的疗效观察[J].中国医院用药评价与分析，2018，18（5）：580-582.
[22] Moriyama T，Oshima Y，Tanaka K，et al. Statins stabilize the renal function of IgA nephropathy [J]. Ren Fail，2014， 36（3）：356-360.
[23] 王宇，古炀晖，程小红，等.525例伴血脂异常IgA肾病患者的临床病理分析[J].暨南大学学报：自然科学与医学版，2018，39（2）：175-184.
[24] Barbour SJ，Espino-Hernandez G，Reich HN，et al. The MEST score provides earlier risk prediction in lgA nephropathy [J]. Kidney Int，2016，89（1）：167-175.